Shares of AstraZeneca PLC (LON:AZN – Get Rating) have earned a consensus rating of “Buy” from the fifteen ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is £104.32 ($135.94).
Several brokerages recently weighed in on AZN. Berenberg Bank increased their price target on AstraZeneca from £100 ($130.31) to £120 ($156.37) and gave the stock a “buy” rating in a report on Monday, April 11th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a £105 ($136.83) target price on shares of AstraZeneca in a report on Tuesday, April 5th. UBS Group set a £105 ($136.83) target price on AstraZeneca in a report on Monday, March 7th. Barclays reissued an “overweight” rating and issued a £115 ($149.86) target price on shares of AstraZeneca in a report on Wednesday. Finally, Deutsche Bank Rese… set a £115 ($149.86) target price on AstraZeneca in a report on Wednesday, April 6th.
Shares of LON AZN traded up GBX 26 ($0.34) during mid-day trading on Monday, hitting £105.36 ($137.29). 1,766,658 shares of the company were exchanged, compared to its average volume of 2,335,011. The company has a quick ratio of 0.67, a current ratio of 1.16 and a debt-to-equity ratio of 82.58. The stock has a 50 day simple moving average of GBX 9,477.54 and a 200-day simple moving average of GBX 8,947.28. AstraZeneca has a 1-year low of GBX 7,237 ($94.31) and a 1-year high of £110 ($143.34). The firm has a market cap of £163.25 billion and a price-to-earnings ratio of 1,727.21.
AstraZeneca Company Profile (Get Rating)
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.